GlassScriptPhysician profile
Bruce D Gooberman
NPI 1568424448
$793.58
in general payments reported to CMS, 2019-2025
17 companies · $115 in 2025
The $115 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $56.47 · 2021: $56.13 · 2022: $219 · 2023: $110 · 2024: $127 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $207.02 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $189.71 | 2019-2025 | Gardasil 9, Proquad, Vaxelis |
| Kaleo, INC. | $57.17 | 2019-2023 | Auvi-Q |
| Tris Pharma INC | $54.03 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $37.64 | 2025 | Neffy |
| Novo Nordisk INC | $34.52 | 2025 | Wegovy |
| Sanofi Pasteur INC. | $32.35 | 2021-2024 | |
| Corium, LLC | $31.74 | 2022-2023 | Azstarys |
| Genzyme Corporation | $28.13 | 2025 | |
| Hologic Sales and Service, LLC | $22.05 | 2024 | Aptima |
| Cognoa, INC. | $20.58 | 2022 | |
| Seqirus USA INC | $14.60 | 2022 | |
| Genentech USA, INC. | $13.75 | 2022 | |
| Abbvie INC. | $13.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.85 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $12.53 | 2020 | |
| Sobi, INC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Gooberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.